Kodiak Sciences Inc Common Stock
KODKodiak Sciences Inc (KOD) is a biotechnology company focused on developing ophthalmology and CNS therapies using its proprietary antibody and antibody conjugate platform. Established to address serious retinal diseases, it works on a range of innovative treatments aimed at unmet medical needs in eye health.
Company News
Several stocks saw significant gains on Thursday, with Ameresco receiving a bullish upgrade from Jefferies, Lithium Americas experiencing potential government interest, and Kodiak Sciences getting an analyst upgrade.
The report provides an overview of the global clinical trials landscape for diabetic retinopathy, including details on trial numbers, enrollment, and status across different regions, countries, phases, and sponsor types. It also highlights prominent drugs and companies involved in these trials.
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
